Innovex Q2 2026 Shows Progress, But Valuation Keeps Us Cautious

What happened

Innovex International reported Q2 2026 results with 9% revenue growth, a 2.2-point gross margin improvement, and robust free cash flow, supporting its transition to a capital-light consolidator. Recent acquisitions TCO Group and DIS are validating the cross-selling model by adding high-margin consumables to the company's global distribution network. Management guided for further margin expansion and EBITDA growth in Q3, signaling confidence in the integration and market share gains. However, the company's GAAP margins remain below adjusted figures, and free cash flow has historically been flattered by asset sales and non-cash items, so sustainability is still unproven. The stock appears fairly valued at current levels, and we prefer to wait for confirmation of clean earnings power before turning more positive.

Implication

The Q2 2026 results are encouraging and suggest the acquisition-driven strategy is working, but we need to see two consecutive quarters of high-teens EBITDA margins and cash-driven FCF to confirm the thesis. The new acquisitions introduce integration risk, and the company's GAAP-to-adjusted gap remains a concern. If Q3 2026 meets guidance and shows no deterioration in underlying profitability, we would likely upgrade to a Buy with a target near the base case of $28. Conversely, if margins slip or free cash flow weakens, the stock could re-rate lower. We recommend monitoring insider activity and acquisition disclosures closely.

Thesis delta

The positive Q2 2026 results and accretive acquisitions strengthen the bull case for Innovex's distribution arbitrage model. However, we maintain our WAIT rating because the stock already embeds significant execution and the GAAP earnings quality remains unproven. We would upgrade to BUY if Q3 2026 confirms sustained margin expansion and cash conversion without one-time gains.